US › Healthcare

Immunitybio Inc (IBRX)

US · Healthcare · Biotechnology

$6.95-2.80%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$44.2M
Revenue YoY
+167.6%
Net profit
$-632.8M
Profit YoY
-388.1%
EPS
$-0.08
EPS estimate
$-0.07
Net margin
-1,431.4%

EPS came in at -0.08 against a street estimate of -0.07 — a miss of 14.3%.

Key statistics

Market cap
$7.51B
Forward P/E
0.0
P/B
0.00
Book value
$-0.83
EPS (TTM)
$-0.85
52-week high
$12.43
52-week low
$1.95
50-day MA
$7.68
200-day MA
$5.92
Beta
0.08

Analyst view

Analysts rate Immunitybio Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $12.75.

Shareholding

Insiders
62.47%
Institutions
17.58%

Largest institutional holders

FundStake
BlackRock Inc2.52%
State Street Corp1.69%
Vanguard Portfolio Management, LLC1.56%
Vanguard Capital Management, LLC1.44%
D. E. Shaw & Co LP1.20%
Geode Capital Management, LLC0.77%
Two Sigma Investments LLC0.42%
Morgan Stanley - Brokerage Accounts0.38%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q3 20262026-07-30
Shareholder vote results · Q2 20262026-06-10
Material agreement · Q2 20262026-05-18
Quarterly report · Q1 20262026-05-07
Results announced · Q2 20262026-05-07
Proxy statement · Q2 20262026-04-30
Annual report FY20252026-02-23
Quarterly report · Q3 20252025-11-05

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immunitybio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.